1. Home
  2. PIII vs TPST Comparison

PIII vs TPST Comparison

Compare PIII & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo P3 Health Partners Inc.

PIII

P3 Health Partners Inc.

HOLD

Current Price

$1.63

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$0.29

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIII
TPST
Founded
2015
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
13.7M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
PIII
TPST
Price
$1.63
$0.29
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $7.75
N/A
AVG Volume (30 Days)
32.6K
★ 182.0K
Earning Date
11-09-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $1,459,080,000.00
$295,000.00
Revenue This Year
$7.84
N/A
Revenue Next Year
$7.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.52
$0.29
52 Week High
$16.89
$4.22

Technical Indicators

Market Signals
Indicator
PIII
TPST
Relative Strength Index (RSI) 21.10 20.25
Support Level N/A N/A
Resistance Level $3.07 $0.56
Average True Range (ATR) 0.39 0.05
MACD -0.08 0.00
Stochastic Oscillator 1.41 4.46

Price Performance

Historical Comparison
PIII
TPST

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: